-

Simulations Plus Sets Date for Fourth Quarter and Fiscal Year 2022 Earnings Release and Conference Call

Conference call to be on Wednesday, October 26, 2022, at 5:00 PM ET

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2022, the period ended August 31, 2022, after the close of the financial markets on Wednesday, October 26, 2022.

The Company will host a conference call on October 26, 2022, at 5:00 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Hayden IR
Mr. Brian Siegel
346-396-8696
brian@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus announced today that it will report 4th quarter and fiscal year 2022 financial results on Oct. 26, 2022, with a webcast at 5pm ET.
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Hayden IR
Mr. Brian Siegel
346-396-8696
brian@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have been published in the Amer...

Simulations Plus Invests in Clinical Development Technology Company Nurocor

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceuti...

Simulations Plus Releases ADMET Predictor® 13

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13...
Back to Newsroom